Maxipime Related Published Studies
Well-designed clinical trials related to Maxipime (Cefepime)
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. [2009.10]
Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison. [2009.04]
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. [2009.04]
Cefepime/clindamycin vs. ceftriaxone/clindamycin for the empiric treatment of poisoned patients with aspiration pneumonia. [2008.08]
Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis. [2008.08]
Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. [2008.05]
Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial. [2008.01]
A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. [2006.08.15]
Cefepime vs. Ampicillin/Sulbactam and Aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial. [2006.06]
Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. [2006.04]
Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. [2006.04]
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. [2005.08]
Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. [2005.01]
Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. [2004.07.15]
A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. [2004]
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. [2003.11]
Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. [2003.09.01]
Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. [2003.07]
Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients. [2003.06]
Antibiotic prophylaxis in elective thoracic surgery: cefuroxime versus cefepime. [2003.04]
Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. [2002.12]
A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections. [2002.10]
Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. [2002.09]
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. [2002.07]
Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. [2002.03]
A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. [2002.01]
Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. [2001.10]
Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. [2001.09]
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. [2001.09]
Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. [2001.07]
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. [2001.06]
Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. [2001.04]
Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. [2001.03]
Ocular penetration of cefepime following systemic administration in humans. [2001.01]
Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. [2001]
[Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli] [2000.12]
Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa. [2000.11]
Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. [2000.09]
A multicenter randomized trial of prophylaxis with intravenous cefepime + metronidazole or ceftriaxone + metronidazole in colorectal surgery. The 230 Study Group. [2000.02]
Cefepime versus ceftazidime for the treatment of serious bacterial infections. [1999.12]
A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. [1999.09]
Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. [1999.08]
A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia. [1999.08]
[Continuous versus intermittent cefepime infusion in critical care. Preliminary results] [1999.05]
Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. [1999.04]
[Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study] [1999.02]
Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). [1998.10]
Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment. [1998.08]
Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. [1998.07.20]
Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. [1998.04]
A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. [1997.12]
Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. [1997.08]
Cefepime versus ceftazidime in the treatment of lower respiratory tract infections. [1997.06]
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. [1997.01]
Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. [1995.04]
Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. [1995.01]
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. [1994.03]
Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections. [1993.11]
Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. [1993.11]
International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. [1993.11]
A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. [1993.11]
Cefepime for infections of the biliary tract. [1993]
A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis. [1993]
A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. [1993]
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. [1992.09]
[Dose finding study of cefepime for chronic respiratory infections] [1992.07]
Tissue concentrations of cefepime in acute cholecystitis patients. [1992.06]
Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. [1991.11]
A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. [1991.10]
Analysis of cefepime tissue penetration into human appendix. [1991]
Well-designed clinical trials possibly related to Maxipime (Cefepime)
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. [2006.02]
Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group. [1998.07]
Current and future management of serious skin and skin-structure infections. [1996.06.24]
Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. [1996.06.24]
Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. [1996.06.24]
A new therapeutic option for the treatment of pneumonia. [1996.06.24]
Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. [1996.06.24]
Other research related to Maxipime (Cefepime)
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. [2009.08]
Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically-Ill Patients with Ventilator Associated Pneumonia. [2009.02.02]
Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. [2009.02]
Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey. [2009.01]
Cefepime-induced nonconvulsive status epilepticus: case report and review. [2009]
Cefepime: a reappraisal in an era of increasing antimicrobial resistance. [2008.12]
Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime. [2008.09]
Acute administration of cefepime lowers L-carnitine concentrations in early lactation stage rat milk. [2008.07]
Renal failure is a risk factor for cefepime-induced encephalopathy. [2008.07]
The safety of cefepime in the treatment of infection. [2008.07]
[The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients] [2008.07]
Population pharmacokinetics of cefepime in neonates with severe nosocomial infections. [2008.06]
Cefepime and its role in pediatric infections. [2008.06]
Cefepime and its role in pediatric infections. [2008.06]
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. [2008.04]
Cefepime for prophylaxis of infections in the surgery of cholelithiasis. Results of a multicentric comparative trial. [2008.04]
Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. [2008.04]
Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment. [2008.04]
The neurotoxicity and safety of treatment with cefepime in patients with renal failure. [2008.03]
[Clinical case of the month. Antibiotics and hemodialysis: three cases of neurotoxicity from Maxipime] [2008.03]
Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. [2008.02]
Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves. [2008.02]
Efficacy and safety of cefepime in late-onset ventilator-associated pneumonia in infants: a pilot randomized and controlled study. [2008.01]
Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. [2007.12]
|
